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ABSTRACT:
An incompletely penetrant COL7A1 mutation causes dystrophic epidermolysis bullosa
and epidermolysis bullosa pruriginosa.
Catherine S. Yang B.A.a, Yin Lu Ph.D.b, Anita Farhi R.N.b, Carol Nelson-Williams
Ph.D.b, Michael Kashgarian M.D.c, Earl J. Glusac M.D.c, Richard P. Lifton M.D.
Ph.D.b, Richard J. Antaya M.D.d, Keith A. Choate M.D. Ph.D.b,d.
a

Yale University School of Medicine, New Haven, CT.
Department of Genetics, Howard Hughes Medical Institute, New Haven, CT.
c, d
Departments of Pathology and Dermatology, Yale University School of Medicine,
New Haven, CT.
b

Epidermolysis bullosa pruriginosa (EBP) is a rare subtype of dystrophic
epidermolysis bullosa (DEB) and is characterized by intense pruritus, nodular or
lichenoid lesions, and violaceous linear scarring most prominent on the extensor
extremities. Remarkably, identical mutations in COL7A1, which encodes an
anchoring fibril protein present at the dermal-epidermal junction, can cause both DEB
and EBP with either autosomal dominant or recessive inheritance. We present one
family with both dystrophic and pruriginosa phenotypes of epidermolysis bullosa. The
proband is a 19-year-old Caucasian female who initially presented in childhood with
lichenoid papules affecting her extensor limbs and intense pruritus consistent with
EBP. Her maternal grandmother was followed by a dermatologist for similar skin
lesions that developed without any known triggers at age 47 and mostly resolved
spontaneously after approximately ten years. The proband’s younger brother
developed a small crop of pruritic papules on his elbows, dorsal hands, knees, and
ankles at age 13. Her second cousin once removed, however, report a mild blistering
disease without pruritus consistent with DEB. Genetic sequencing of the kindred
revealed a single dominant novel intron 47 splice site donor G>A mutation, c.4668+1
G>A, which we predict leads to exon skipping. Incomplete penetrance is confirmed in
her clinically-unaffected mother, who also carries the same dominant mutation. The
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wide diversity of clinical phenotypes with one underlying genotype demonstrates that
COL7A1 mutations are incompletely penetrant and strongly suggests that other
genetic and environmental factors influence clinical presentation.
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INTRODUCTION:
The broad term ‘epidermolysis bullosa’ (EB) was first coined by German
dermatologist Heinrich Koebner in 1866 to describe a group of inherited traumainduced blistering disorders. Since its introduction, EB has been stratified into three
subtypes depending upon the ultrastructural findings on electron microscopy: 1) EB
simplex, denoting non-scarring blistering at the level of the epidermis; 2) junctional
EB for blistering at the level of the lamina lucida; and 3) dystrophic EB (DEB) for
scarring blisters at the level of the sub-lamina densa. A recent addition to the EB
family in 2008 is Kindler's syndrome, a separate entity because its blistering can
occur at any of the three cleavage planes (1). EB is a relatively common, prototypical
genodermatosis with an estimated prevalence of 8.22 per 1 million people worldwide
(2), although some believe this number to be an underestimate that does not capture
many individuals falling within the milder spectrum of DEB (3).

DEB is a clinically heterogenous class of diseases that is caused by both dominant and
recessive mutations in type VII collagen, the major anchoring fibril located below the
basal lamina. Generalized dominant DEB, a term encompassing both CockayneTouraine and Pasini-type DEB, tends to produce a mild phenotype of localized
blistering at sites of trauma that heal with milia and atrophic scarring. In some
patients, the only manifestation of dominant DEB is isolated nail dystrophy or subclinical blistering. Severe generalized recessive DEB (RDEB-sev gen, previously
Hallopeau-Siemens RDEB), on the other hand, often presents with whole-body
blisters and extracutaneous manifestations such as excessive dental caries, esophageal
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strictures, and colitis. These patients suffer from painful and mutilating contractures
and have a shortened lifespan due to repeated infections or frequent, aggressive
squamous cell carcinomas. An intermediate form named recessive DEB generalized
other (RDEB-O, previously non-Hallopeau-Siemens RDEB or RDEB-mitis) also
demonstrates extensive blistering and extracutaneous involvement but is a milder
phenotype than RDEB-sev gen with decreased mortality. In addition to these three
common subtypes of DEB, there are at least five other, rarer forms of DEB including
epidermolysis bullosa pruriginosa (1).

Epidermolysis bullosa pruriginosa (EBP) was first described by McGrath et al in 1994
(4) and is distinguished from other types of DEB by its intense pruritus, lichenified or
nodular prurigo-like lesions, and violaceous linear scarring. Blisters and erosions,
which are the hallmark features of DEB, are rarely seen in EBP. The extensor
extremities, particularly the shins, are commonly affected sites. Excoriations, milia,
albopapuloid lesions, and nail dystrophy are often apparent whereas teeth and
mucosal membranes are usually unaffected. Extracutaneous manifestations are
extremely rare; only one EBP patient with gastrointestinal involvement has been
reported in the literature thus far (5). Unlike DEB, which often manifests at birth,
many cases of EBP do not present until adulthood (5–10). The oldest reported age of
onset is 71 years (11). As such, EBP can be mistaken for acquired disorders such as
prurigo nodularis, lichen simplex chronicus, hypertrophic lichen planus, or
psychogenic pruritis.
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A. Molecular processing of collagen VII
All forms of DEB, including EBP, are caused by mutations in the gene encoding for
type VII collagen, COL7A1. The COL7A1 gene, located on chromosome 3p21,
contains 32 kilobases (12). The gene is transcripted into an 8.9 kb mRNA product,
which is then translated into a 2944 amino acid proα1 polypeptide (13). The protein
consists of three domains: a large non-collagenous (NC-1) domain from exon 1 to 28,
a triple helical glycine-X-Y repeat domain from exon 29 to 111 with several short
interruptions, and a smaller non-collagenous (NC-2) domain from exon 112-118. In
the extracellular matrix, three proα1 polypeptides assemble into a collagen VII
homotrimer. Two homotrimers form an antiparallel dimer and an aggregate of dimers
assemble into anchoring fibrils with intermolecular disulphide bonds and
transglutaminase cross-links for stabilization (14). The NC-1 domain on both ends of
the anchoring fibrils adheres to the basement membrane above and the collagen IV
fibrils in the dermis below (12,13).

Over 300 mutations in COL7A1 have been identified in patients with DEB (12,15)
and there appears to be some genotype to phenotype correlation. Typically, missense
mutations and in-frame splice site mutations, deletions, and insertions are dominantly
inherited while mutations resulting in premature termination codons (PTCs) are
recessively inherited. Dominant DEB, which has milder clinical phenotypes, usually
shows normal quantity and/or appearance of anchoring fibrils on biopsy. These
mutations cause qualitative changes such as disrupting the correct processing of
collagen VII or decreasing the stability of the anchoring fibrils. Recessive DEB,
however, is more severe, with decreased amounts of collagen VII apparent on electron
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microscopy and immunofluorescence staining. Patients with RDEB-sev gen typically
possess two PTCs leading to no functional protein whereas RDEB-O contain one PTC
and one missense mutation or two missense mutations causing malfunctioning or
absent anchoring fibrils at the dermal epidermal junction (12). Hence, as expected, the
severity of the DEB depends on the amount of collagen VII present.

Comparatively, over 50 mutations in COL7A1 have been reported in EBP. The
majority of the mutations are dominant missense alterations in the amino acid glycine
within the triple helical domain, although exceptions exist (5,6,9). The
immunofluorescence pattern in EBP typically resembles that of DDEB, with staining
similar to normal skin or slightly decreased. No clear pattern of mutations leading to
EBP emerges, but exon 87 skipping in particular has been suggested as predictive for
EBP (10,16–18). At least six mutations either within the splice site donor or within
exonic regulatory sequences have been identified in families with EBP (9–11,16–20).
However, exon 87 skipping has also been described in dominant DEB (21) and has
more recently been suggested to be prognostic for a mild phenotype of DEB rather
than specifically EBP (22).

B. Hypotheses regarding the etiology of the pruritus in EBP
The cause of pruritus in EBP is unknown. Remarkably, the identical mutation in
COL7A1 can cause DEB in one patient and EBP in another (5–9,23). Alternate
hypotheses regarding the origin of pruritus have included elevated serum IgE levels
(9,20,24), concurrent filaggrin mutations leading to atopy (5), increased expression of
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matrix metalloproteinase 1 (MMP1) causing imbalance of collagen degradation
(10,25), and increased cytokine IL-31 (26). None of these hypotheses uniformly
accounts for pruritus observed in EBP. A more thorough discussion of these theories
is presented below.

i.

Elevated serum IgE levels

Elevated serum IgE levels initially seemed like a promising correlation with the
hallmark pruritus of EBP. Early case reports had noted elevated IgE levels in their
patients (24,27). In one study, seven out of nine patients studied had elevated IgE
levels, several with values threefold higher than the upper limit of normal (20).
However, in a 2006 study by Drera et al, only two out of seven EBP patients had
elevated IgE levels (9). Furthermore, in a control group of patients with non-pruritic
DEB, two out of six also had elevated IgE and thus the marker proved to be poorly
specific for EBP (20). In subsequent reports, it quickly became apparent that the link
between hyper-IgE levels and EBP was tenuous at best, as the overwhelming majority
of patients with EBP have normal IgE levels (5,16,17).

ii.

Co-existing pruritic disorder

The initial correlation between IgE levels and EBP induced a discussion of whether
these patients possessed an atopic diathesis. In the initial report by McGrath et al,
only one of the seven patients presented had a history of eczema, asthma, or
rhinoconjunctivitis (4). Among the patients with elevated IgE levels reported in other
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case series, several had either a personal or family history of atopic disease (27), but
most were unexplained (9,20,28). Yet, in many instances, adequately treating the
atopy with corticosteroids induced improvement in the patient’s cutaneous lesions of
EBP as well (9,27).

Other etiologies of pruritus such as thyroid dysfunction, cholestasis, end stage renal
disease, iron deficiency, and Hodgkin’s lymphoma are routinely screened for and
rarely found (4,9,20). However, many patients recall mild DEB that evolve into EBP,
often attributing this to the onset of pruritus due to an external cause such as
pregnancy, thyroid cancer, diabetes mellitus, or even varicella virus infection
(5,6,8,11) although correction of these diseases did not lead to improvement of their
cutaneous lesions. An interesting observation is the onset of pruritus with onset of
puberty, suggesting a possible modifying role for the hormonal cascades associated
with adolescence acting as a trigger (9,29). However, many others report
improvement of their lesions during puberty (6,18) and thus again, no clear pattern
emerges.

iii.

Filaggrin mutations

For years, mutations in filaggrin, a protein integral to an intact skin barrier, was
suspected to predispose children to atopic dermatitis and ichthyosis vulgaris (30), but
further characterization of this association proved elusive due to the highly repetitive
sequences precluding sequencing until 2007 (31). This seminal paper documented two
filaggrin variants with a prevalence of approximately 9% in the European population
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and three additional less common variants that cumulatively accounted for another
2.6% (30,31). Schumann et al postulated that mutations in filaggrin may further
compromise the skin barrier and thus correlate with the pruritus of EBP (5). They
screened seven patients with EBP for the two most common filaggrin variants in the
European population, R501X and 2282del4, but found neither in all of the patients.

iv.

Matrix metalloproteinase-1 expression

Matrix metalloproteinase-1 (MMP1) degrades extracellular proteins such as type VII
collagen and is integral to tissue remodeling and wound healing. Titeux et al
described a polymorphism in the gene promoter of MMP1 that increases its
expression, leading to more severe RDEB than those who did not carry the
polymorphism (25). The addition of a nucleotide G creates a new ETS transcription
binding site in the promoter, thus enhancing the expression of MMP1. Almaani et al
postulated that the increased degradation of type VII collagen by MMP1 could lead to
secondary inflammatory changes causing pruritus (32). They screened a cohort of 27
patients with EBP, 23 patients with DDEB, 25 patients with RDEB, and 50 control
subjects for the MMP1 promoter polymorphism, rs1799750: (-)>G. Although the
researchers found a higher frequency of the 2G allele in RDEB group, there was no
significant difference between the 1G and 2G MMP1 alleles among the EBP, DDEB,
and control groups (32).
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v.

Immunomodulatory factors

Given the success of immunomodulatory agents such as cyclosporine and tacrolimus
in the treatment of EBP, a hypothesis regarding the effect of cytokines and other
immunomodulatory factors has been proposed (9,33). Overexpression of cytokine
interleukin-31 (IL-31) has been found to be upregulated in patients with atopic
dermatitis and also to induce severe itching and eczema in mice (34,35).
Polymorphisms within cytokine IL-31 has been linked to increased stimulation of Tcell antibodies and hence, eczema susceptibility (36). Using the same cohort of EBP,
DDEB, RDEB, and unaffected patients described above in ‘iv’ (32), the group tested
the IL-31 haplotype and again found no statistically significant differences in allele
frequencies. However, the authors readily admit the limitations of their study, which
only examined the genetic sequence and did not measure the amount of IL-31 present
in patients’ serum.
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STATEMENT OF PURPOSE
In order to further elucidate the clinical heterogeneity of DEB and EBP, we studied
one kindred with both of these phenotypes (Figure 1). The proband is a 19-year-old
female of Italian descent who was referred to Yale Dermatology Associates at age
five with new-onset pruritic lesions on her right medial malleolus and chin. Over
time, the patient’s pruritus gradually worsened with extension of lesions to her
extensor extremities bilaterally, the peri-umbilicus, the sacrum, and the upper midback. No triggers were reported. She was otherwise healthy, without a history of
atopy. Her parents are non-consanguineous and neither reported any history of atopy,
skin fragility, or pruritic dermatoses. The proband’s grandmother developed similar
lesions at age 47, which persisted for approximately ten years before mostly resolving
spontaneously. The proband’s 15-year-old brother also developed a few pruritic
papules at age 13, but was much less extensively affected. Meanwhile, her second
cousins once removed and their father report only trauma-induced blistering. The
objective of this study was to better characterize the genetic complexity of COL7A1
mutations causing DEB and EBP in this kindred.
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Figure 1. DEB and EBP phenotypes independently segregate in one kindred with
incomplete penetrance. (A) Individuals in EBP kindred 100 show either an
epidermolysis bullosa pruriginosa phenotype (black symbols) or a dominant
dystrophic epidermolysis bullosa phenotype (grey symbols). * indicates genetic
analysis has been performed.
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METHODS:
This study protocol was approved by the Human Investigation Committee at Yale
University. The proband (100-1), her immediate family members (100-2-5), and two
members from her extended family (100-6, 100-7) were clinically examined by
dermatologists between 1997 and 2011. Two family members reported to have DEB
were unable to participate in this study (100-8, 100-9).

In the proband, clinical diagnosis was verified with skin biopsies of lesional sites
performed with local anesthetic. The biopsy specimens were embedded for light and
electron microscopy by Yale Dermatopathology Labs (New Haven, CT).
Immunofluorescence staining for collagen IV, VII, and keratin 14 was performed by
Beutner Laboratories (Buffalo, NY). Complete blood count, IgE levels, thyroid
function, renal function, AST/ALT, bilirubins, iron, and ferritin were tested in the
proband to exclude alternative causes of pruritus.

Genomic DNA was extracted from peripheral blood lymphocytes in the proband and
immediate family members using phenol-chloroform extraction. Primer sets
representing all 118 exons of COL7A1, including intron-exon boundaries, were
generated with Primer3 (http://frodo.wi.mit.edu/primer3/) using the hg18 version of
the genome masked to exclude DNA sequence repeats (GenomeMasker:
http://bioinfo.ebc.ee/snpmasker/) as the template. We also generated primers for the
five most common filaggrin mutations in European populations (R501X; 2282del4;
3702delG; R2447X; and S3247X) (31) and for the previously reported promoter SNP
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in MMP1 (rs1799750: (-)>G) hypothesized to account for the pruritus of EBP (25).
Polymerase chain reaction was carried out on 50 ng of DNA using KAPA2G Fast
Polymerase (Kapa Biosystems; Woburn, MA) and then sequenced. The sequences
were compared to the human reference sequence (hg18, NCBI) utilizing Sequencher
(Gene Codes; Ann Arbor, MI). A single sequence variant in COL7A1 was identified
which was not found in SNP databases and in sequencing of 95 ethnically-matched
unrelated controls without history of skin disease.

Review of the literature was performed using PUBMED search term “epidermolysis
bullosa pruriginosa” between June 2009 and October 2011 and results are
summarized in Table 1. Forty-two papers were identified; thirteen papers were
excluded either because the case presented was not affected with epidermolysis
bullosa pruriginosa or because no genetic analysis was performed. Additional
mutations were found using the International Dystrophic EB Patient Registry database
(http://www.deb-central.org). Each mutation was then surveyed using the Human
Gene Mutation Database (http://www.hgmd.org/) and recent reviews of COL7A1 gene
(12,15) to determine if it had been previously reported to cause DEB. Any
discrepancies between sources were resolved by referring to the original article
reporting the mutation in question.

Statement of contributions of authors:
Anita Farhi was actively involved in patient recruitment, in acquiring HIC approval
for this study, and in obtaining peripheral blood samples from the subjects of this
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study. Carol Nelson-Williams extracted the DNA from the blood samples. Drs.
Richard Antaya and Keith Choate performed the clinical characterization of all the
subjects examined and the skin biopsies when appropriate. Dr. Earl Glusac performed
the histopathological analysis of the skin biopsies. Dr. Michael Kashgarian performed
the electron microscopy readings of the proband's biopsy. I designed and executed the
study, performed all of the PCRs, and analyzed all of the DNA sequence readings.
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RESULTS:
On full skin examination, the proband displayed excoriated, lichenoid papules with
milia coalescing into confluent plaques (Figure 2). There was no nail dystrophy and
ancillary lab tests to evaluate for pruritus were all within normal limits. Skin tests for
common food allergens and standard inhalants were negative, except for an allergic
reaction to penicillin at age 9. Histopathology of her lesions showed a subepidermal
cleft with milia and electron microscopy showed a subepidermal cleft with lysis and
separation of collagen fibrils in the reticular dermis. There was no evidence of
amyloid deposition. Direct immunofluorescence showed normal quantities and
immunolocalization patterns of collagen IV, collagen VII, and keratin 14 (Figure 3).
Altogether, these findings supported a diagnosis of EBP.
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Figure 2. Clinical features of EBP in proband, 100-1. (A-C) Lichenoid papules and
nodular prurigo-like lesions on shins bilaterally (A), dorsal hand (B), and upper back
(C). Many papules are excoriated.

Figure 3. Histologic features of EBP in proband, 100-1. EBP is characterized by
subepidermal clefting and disruption of anchoring fibrils. (A) Hematoxylin and eosin
stain of affected skin shows subepidermal clefting (black arrow) and milium, 20X. (B,
C) Direct immunofluorescence staining shows normal pattern and amount of collagen
IV and VII. (D) Electron microscopy of skin adjacent to a nodular lesion shows lysis
and separation of collagen fibrils in the reticular dermis (white arrow). * indicates
subepidermal cleft.
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The only remnants of EBP in the propositus’ grandmother were macular scars on her
upper back and intermittent clusters of pruritic papules on her upper extremities (Fig.
4A). The proband’s brother had few, isolated pruritic papules on his dorsal hands,
elbows, knees, and ankles (Fig. 4B). The proband’s second cousin once removed
exhibited trauma-induced blistering, atrophic scarring, and few milia on his extensors
(Fig. 4C). Her mother had no skin findings on full skin examination.

Figure 4. Clinical heterogeneity of EBP and DEB in kindred EBP 100. (A) Cluster
of papules on the right hand of the proband’s maternal grandmother, 100-6. (B)
Lichenoid papules on the left index finger of the proband’s 15-year-old brother, 100-4.
(C) Blister and atrophic scarring on knee of the proband’s second cousin once
removed, 100-7.
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Sanger sequencing of COL7A1 in this kindred revealed a novel heterozygous splice
site mutation in intron 47, c.4668+1 G>A, in the proband, her affected family
members, and her unaffected mother (Figure 5). This mutation abolishes the intron 47
splice donor; similar mutations frequently lead to exon skipping or use of cryptic
splice sites nearby (9,16,18,19). Fifty-six mutations causing EBP are reviewed in
Table 1 and Figure 6. All of the dominant mutations, including c.4668+1 G>A,
interfere with the consecutive Gly-X-Y repeats in the triple helical domain of the
protein. Only ten recessive cases were identified.

Figure 5. DEB and EBP phenotypes result from the same COL7A1 mutation with
incomplete penetrance. Sanger sequencing of exons and intron/exon boundaries of
COL7A1 was performed. (A) WT junction between exon 47 and intron 47 shows
position of normal splice donor. (B) A heterozygous c.4668+1 G>A mutation
abolishes the intron 47 splice donor in all individuals with EBP (100-1, 4, 6), in a
single individual with DEB (100-7), and in the unaffected mother of the index case
(100-2). Wild type sequence was present at this position in the unaffected father (1003) and unaffected sibling (100-5) of the index case.
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Mutation

Exon

p.R28G/
p.G2366A

1/92

p.R51G/
p.R2492X

2/98

c.425A>G/
c.7344G>A

3/95

c.425A>G/
p.E2736K

c.497insA/
p.G1347W

c.4668+1 G>A
p.G1572A/
c.7787delG
p.R1630X/
c.7344G>A

3/110

4/34

Previously
reported to
cause DEB?

Age of onset

Ethnicity

Sex IgE level

Other affected
family members?

Reference

Missense/
Missense

G2366N:
RDEB-O

DEB since 8
y/o; EBP
developed
after first
pregnancy

Italian

F

Normal

Brother with naildystrophy-only
DEB

Pruneddu,
2010

Missense/
PTC
Splice
PTC/
Splice PTC

c.7474C>T:
RDEB-O

13 y/o

Italian

M

Normal

None

Drera, 2006

Both:
RDEB-O

12 y/o

Italian

F

Normal

None

Drera, 2006

RDEB-O

DEB since 6
y/o; EBP
developed at
53 y/o

Caucasian

M

Normal

None

Schumann,
2008

c.497insA:
RDEB-sev
gen
G1347N:
RDEB-O

8 y/o

Caucasian

F

Normal

None

Schumann,
2008

No

5 y/o

Italian

F

Normal

No

NA

NA

NA NA

R1630X:
RDEB-sev

8 y/o

Italian

F

Effect

Splice
PTC/
Missense
PTC/
Missense

In-frame
exon
skipping
Missense/
48/104
PTC
Nonsense/
51/95
Splice PTC
47

c.425A>G:

Normal

Multiple family
members w/ DDEB This report
spectrum
Almaani,
NA
2011
None

Drera, 2006
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p.R1630X

gen
c.7344G>A:
RDEB-O
RDEB-sev
gen

1 y/o

Caucasian

F

Normal

None

Schumann,
2008

NA

Mother and sister
w/ toenail
dystrophy-only
DEB

Tey, 2011

51

Nonsense

c.5399+1G>C

In. 55

In-frame
exon
skipping

No

6 y/o

Caucasian

M

p.G1755D

59

Missense

No

NA

NA

NA NA

NA

p.G1755D

59

Missense

No

39 y/o

Italian

F

Normal

p.G1755D

59

Missense

No

8 y/o

Turkish

F

Normal

None
Mother with naildystrophy-only
DEB

p.G1770D

61

Missense

RDEB

NA

NA

NA NA

NA

Almaani,
2009

p.G1773R

61

Missense

DDEB

9 y/o

Chinese

M

Normal

Mom and maternal
grandfather w/
mild phenotype

Jiang, 2011

p.G1791E

61

Missense

No

Infancy

Caucasian

F

NA

None

Mellerio,
1999

c.5532+1G>A/
c.7786delG

In 64/
Ex104

In-frame
exon
skipping/
PTC

c.7786delG:
RDEB-O

Infancy

Caucasian

F

NA

None

Mellerio,
1999

p.G1860R

66

Missense

No

NA

NA

NA NA

NA

p.G1913R

69

Missense

No

NA

NA

NA NA

NA

Posteraro,
2005
Drera, 2006
Schumann,
2008

Almaani,
2009
Almaani,

20

2009
p.Q1924P/
c.6619-2A>T

p.G2028R

Ex 69/
In 82

73

Missense/
In-frame
exon
skipping

No

Missense

DDEB and
RDEB

NA

20 y/o

p.G2028R

73

Missense

DDEB and
RDEB

p.G2034R

73

Missense

DDEB

p.G2034W

73

Missense

DDEB

p.G2037E

73

Missense

DDEB

DEB since 1
y/o; EBP
developed at
18 y/o
NA
DEB since
birth; EBP
developed at 7
y/o
NA

p.G2040D

73

Missense

DDEB

p.G2073V

75

Missense

p.G2079R

75

p.G2159E
p.G2210V/
p.G2791W

Middle
Eastern

Japanese

NA NA

NA

Abu Sa’d,
2006

F

NA

Father, aunt, and
paternal
grandmother with
EBP

Murata,
2000

Normal

Grandmother,
brother, and
daughter with DEB

Schumann,
2008

Caucasian

F

Chinese

NA NA

NA

Chen, 2000

Caucasian

F

Grandmother,
father, and sister
have DEB

Schumann,
2008

NA

NA NA

NA

Infancy

Caucasian

F

Elevated

None

RDEB-O

10 y/o

Italian

F

Elevated

Father with EBP

Missense

No

NA

NA

NA NA

NA

79

Missense

No

NA

NA

NA NA

NA

83/113

Missense/
Missense

G2791W:
DDEB

NA

Aboriginal NA NA

Normal

Multiple family
members w/
DDEB-Pr and

Unpublished
Ozanic,
2005
Drera, 2006
Abu Sa’d,
2006
Almaani,
2009
Dang, 2007
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Pasini subtype
RDEB

37 y/o

Caucasian

F

NA

NA

Almaani,
2009

No

NA

NA

NA NA

NA

Abu Sa’d,
2006

No

NA

NA

NA NA

NA

Missense

No

NA

NA

NA NA

NA

85

Missense

No

NA

NA

NA NA

p.G2242E

85

Missense

No

12 y/o

Japanese

F

NA

p.G2242R

85

Missense

No

Teens

Chinese

F

NA

p.G2242R

85

Missense

No

7 y/o

Caucasian

M

NA

p.G2242W

85

Missense

No

10 y/o

Chinese

M

Elevated

p.G2251E

86

Missense

DDEB

25 y/o

Chinese

F

Normal

p.G2251E

86

Missense

DDEB

1 month old

Japanese

M

NA

NA
Son w/ bullous
dermolysis of the
newborn
Father, brother,
aunt, and cousin
affected with mild
EBP
Father with mild
EBP
Father,
grandfather, and
paternal uncle with
EBP
4 siblings and
mother with EBP;
2 unaffected
siblings with
mutation
Unaffected father

p.G2213R

83

Missense

c.6652-2A>G

83

p.G2239D

85

In-frame
exon
skipping
Missense

p.G2239V

85

p.G2242E

Tamai, 1998
Almaani,
2011
Tamai, 1998
Murase,
2011
Lee, 1997
Mellerio,
1999
Shi, 2009

Ee, 2007
Takayashi,
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w/ mutation
Multiple family
members w/
blistering and nail
dystrophy

2011

c.6846G>C

87

In-frame
exon
skipping

No

3 kindreds

Danish

NA NA

p.G2287R

87

Missense

DDEB

71 y/o

Japanese

M

Normal

c.6863del16

87

PTC

No

11 y/o

Hispanic

M

NA

p.G2290A

87

Missense

No

40s

Caucasian

F

NA

c.6899+2A>G

87

No

< 35 yo

Chinese

M

NA

18 other family
members with EBP

Jiang, 2002

c.6900+1G>T

In. 87

DEB

2 month old

Chinese

M

Normal

11 other family
members with EBP

Ren, 2007

c.6900+1G>C

In. 87

No

20 y/o

Chinese

M

Normal

Multiple affected
family members

Jiang, 2011

No

30 y/o

Italian

F

Elevated

Normal

c.6900+2delTGAT In. 87

In-frame
exon
skipping
In-frame
exon
skipping
In-frame
exon
skipping
In-frame
exon
skipping

c.6900+4A>G

In. 87

In-frame
exon
skipping

RDEB-sev
gen

38 y/o

Italian

F

p.G2360R

92

Missense

No

NA

NA

NA NA

None

Covaciu,
2011
Hayashi,
2011

Daughter with mild
Mellerio,
EBP; 5 generation
1999
family with DEB
Almaani,
NA
2009

16 members in 5
generations with
skin lesions
5 other affected
members in 4
generations with
skin lesions
NA

Drera, 2006

Drera, 2006
Almaani,

23

2011
p.G2366V

92

Missense

RDEB-O

20s

Chinese

F

Normal in
proband;
elevated in
son

p.G2369S

93

Missense

RDEB

17 y/o

Pakistani

M

NA

p.G2508D

100

Missense

No

NA

NA

NA NA

NA

p.G2517D

100

Missense

No

NA

NA

NA NA

NA

p.G2623V

105

Missense

RDEB-O
and DDEB

8 y/o

Caucasian

M

Normal

Brother with DEB

p.G2626D

106

Missense

No

2 y/o

Chinese

F

NA

4-generation
family with skin
lesions

Wang, 2007

p.G2680D

108

Missense

No

NA

NA

NA NA

NA

Almaani,
2011

p.G2701W

109

Missense

No

25 y/o

Chinese

F

Normal

p.G2713R

110

Missense

DDEB

29 y/o

Caucasian

F

NA

p.G2713R

110

Missense

DDEB

27 y/o

Turkish

F

NA

p.G2719D

110

Missense

No

6 y/o

Caucasian

F

NA

Son and daughter
with EBP
None

Unaffected mother
w/ mutation
Father and nephew
with DEB

Chuang,
2004
Mellerio,
1999
Almaani,
2011
Almaani,
2011
Schumann,
2008

Jiang, 2011

Mellerio,
1999
Broekaert,
None
2006
Brother and mother Riedl, 2009

Table 1. Reported EBP mutations organized by position within COL7A1. We found 61 reports of EBP. In 27 cases, other family members
were affected with DEB and its variants. Of the 56 different mutations found, only 34 mutations were not previously reported to cause either
DDEB or RDEB. All probands have unifying features of pruritus, lichenoid papules, and/ or prurigo-like nodules most commonly on the shins.
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Many additionally presented with milia and nail dystrophy. Missense mutations are denoted using protein nomenclature while other mutations
consisting of, but not limited to, splice site mutations, insertions, and deletions are denoted using the coding sequence. AR = autosomal
recessive; AD = autosomal dominant; DDEB = dominant dystrophic epidermolysis bullosa; RDEB-sev gen = severe generalized recessive
dystrophic epidermolysis bullosa; RDEB-O = generalized other recessive dystrophic epidermolysis bullosa; In = intron; X = termination codon;
N = any protein; NA = not available; ND = not detected.

Figure 6. COL7A1 mutations reported to
cause EBP. Fifty-six mutations are
represented. Missense and nonsense
mutations are represented using the protein
sequence whereas splicing mutations,
deletions, and insertions are represented
using the cDNA sequence. The mutation
identified in this family is bolded and
denoted by an asterisk (*). Recessive
mutations appear above the protein
schematic and dominant mutations appear
below.
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Recognizing that filaggrin mutations could modify the phenotypes observed in this
kindred (30,31), we performed sequencing of the five most common FLG variants in
the European population in our patient and found none. We also addressed the
findings of another group which suggested that a promoter SNP in MMP1 leads to an
imbalance of collagen degradation secondary to overexpression of matrix
metalloproteinase 1 with ensuing inflammation and pruritus (25,32). Sequencing of
the proposed transcription factor binding site (rs1799750: (-)>G) of MMP1, however,
did not reveal any sequence differences between the proband and her mother.
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DISCUSSION:
Intra-familial differences in clinical manifestations of EBP is well described in the
literature (8,18,37,38). One member of the family might suffer from severe EBP while
another from a milder EBP (17,20,39), nails-only DDEB (5,6,40), generalized DDEB
(5,18,20), rarer variants of DEB (29,38), or even no phenotype at all (8,17,37). For
EBP, this phenomenon has been attributed to a presumed adult onset, and attempts
have been made to predict a phenotype in infants or children based on their genetic
mutation and family history (8,21,29). However, the pattern is not consistent and
others report affected children and a clinically unaffected parent carrying the mutation
(37). In our case, although the proband and her brother presented in childhood, their
grandmother developed EBP at age 47 and their 46-year-old mother currently has no
skin findings despite carrying the same dominant mutation.

The heterogeneity of phenotypes even within one family can be partially explained by
the incomplete penetrance of COL7A1 gene mutations. In accordance with previous
reports, no clear pattern emerged from our attempt to correlate COL7A1 gene
mutations with disease phenotype. Most of the pathogenic mutations in EBP are
dominant and within the triple helix, thus altering the Gly-X-Y amino acid triplet
integral for collagen stability and tensile strength. Of the ten recessive cases found in
our review of the literature, seven contain a combination of loss-of-function/gain-offunction mutation, suggesting that the gain-of-function mutation is in reality the
causative allele while the other allele includes a silent mutation or SNP (Table 2).
Clinically, the mild blistering phenotype of EBP usually resembles that of DDEB
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more than RDEB and only rarely is quantitative or qualitative changes in type VII
collagen noted upon biopsy.
Case
1
2
3
4
5
6
7
8
9

Mutation 1 (Effect)
p.R28G (missense)
p.R51G (missense)
c.425A>G (splice PTC)
c.425A>G (splice PTC)
c.497insA (PTC)
p.G1572A (missense)
p.R1630X (nonsense)
c.5532+1G>A (in-frame exon
skipping)
p.Q1924P (missense)

10

p.G2210V (missense)

Mutation 2 (Effect)
p.G2366A (missense)
p.R2492X (PTC)
c.7344G>A (splice PTC)
p.E2736K (missense)
p.G1347W (missense)
c.7787delG (PTC)
c.7344G>A (splice PTC)
c.7786delG (PTC)
c.6619-2A>T (in-frame exon
skipping)
p.G2791W (missense)

Table 2. Reported mutations causing recessive EBP. The majority of these cases
have one mutant allele predicted to result in loss of function and a second gain of
function mutant allele expected to contribute to disease phenotype, giving essentially
mono-allelic expression. Exceptions include cases 1, 9, and 10 in which two gain-offunction mutations are present. The mutations c.425 A>G, c.497insA, and R2492X
are predicted to undergo nonsense-mediated decay and thus would not be expressed
(41). In Case 10, the authors postulated that previously reported G2791W was the
relevant mutation and that G2210V is a polymorphism found in Australian
Aboriginals (38). The putative causative mutations are bolded, based on prior reports
of the same mutation causing EBP or presumed deleterious effect on the encoded
protein.

Overwhelmingly, the EBP patients presented in the research literature and
summarized in Table 1 are from institutions that can afford genetic sequencing, that
is, those located in Western Europe, China and Japan, Australia, and the USA. Only a
few case reports have been published from India, but none offer a genetic analysis and
some did not perform the necessary biopsies to rule out other causes of the lesions
such as lichen amyloidosis or prurigo nodularis (42,43). There is a dearth of genetic
information known about populations in the Middle East, Africa, and South America,
although these kindreds often present with unique COL7A1 mutations that may
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perhaps lead to new insights regarding the phenotypic variability in this
genodermatosis (44).

The mutation identified in this study, c.4668+1 G>A, is located at the conserved
splice site donor of intron 47, which we predict leads to in-frame exon 47 skipping
based upon previous studies investigating splice site mutations (20,40,44). Although
we did not confirm the altered protein product with reverse transcriptase PCR, we
hypothesize that two mRNA products would be isolated from the proband and all
other carriers of the heterozygous mutation. Exon 47 contains 11 amino acids and is
located within the triple helix. Exclusion of this exon is expected to alter the stability
of collagen VII anchoring fibrils in the papillary dermis.

Notably, affected individuals can transition from a DEB to an EBP phenotype; most
attribute this to the development of pruritus, which then, in turn, causes the lesions of
EBP (5,6,9,24,27). This finding lends support to the question of whether EBP is a
unique disease entity or whether the phenotype is due to pruritus superimposed on
DEB (4,11,29). Although some patients report an initiating incident such as thyroid
dysfunction or chickenpox infection, most EBP cases did not improve when the
pruritic disease resolved and the majority of EBP patients do not remember an
inciting factor (5). Thus, there may be an element of recall bias in these case reports,
but larger trials are difficult to conduct given the rarity of EBP. In our kindred, neither
the index case nor her brother is atopic, and although their grandmother developed
hypothyroidism in her 30s, she was clinically euthyroid at the time of her EBP
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eruption nearly fifteen years later. Yet, the question of whether itch is a symptom of
EBP versus integral to the pathogenesis of EBP is still being debated.

EBP is notoriously challenging to treat. Therapeutics reported to be successful in the
literature include high-dose topical and oral corticosteroids (4,9), cyclosporine
(33,40), topical tacrolimus (10,45), and thalidomide (46). However, none of these
therapeutics work universally for patients with EBP. In a cohort of eight patients on
tacrolimus, only one patient reported significant relief and three others reported partial
relief (32). Corticosteroids has a similar, if not higher, failure rate (4,9) and the
number of patients treated with cyclosporine is too few to gauge its efficacy. The
exact mechanisms by which these treatments affect EBP is still unknown, but the
common endpoint among them is the dissolution of pruritus with improvement of the
cutaneous lesions manifesting several months later (9,32,46). This observation leads
to the possibility of new medications directed at novel targets as we learn more about
the pathophysiology of pruritus.

Our patient was treated with numerous medications including topical and systemic
corticosteroids, anti-histamines, anti-opiates, capsaicin, TNFα inhibitors, and
phototherapy with minimal success. Oral cyclosporine 5 mg/kg mildly improved her
pruritus, but was discontinued after five months due to marked gingival hyperplasia.
Low-dose thalidomide has been documented to improve EBP, most likely via
immunomodulation of the production of TNFα, IFNγ, and other cytokines (46). Our
patient was started on 100 mg/day thalidomide and reported decreased pruritus and
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flattening of her lesions within two months. She developed mild peripheral
neuropathy after four months of treatment so the dose was decreased to 50 mg/day
with resolution of her paresthesias and continued efficacy. After nine months of
thalidomide treatment, the proband’s pruritus is well-controlled and her lesions
continue to flatten leaving hypopigmented macules and milia (Figure 7).

Figure 7. Improvement of skin lesions with systemic thalidomide administration.
The index case was started on thalidomide 100 mg daily and improved gradually with
most apparent results at two months. Shins (A), left dorsal hand (B), and mid-upper
back (C) show flattening of papules with less excoriation after six months of
treatment.
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Mutational analysis of COL7A1 gene in patients suspected of DEB is not currently
used for diagnosis, but rather only for the purposes of research or for genetic
counseling. As genetic sequencing becomes easier and more cost-effective, it is
plausible that it will become more routinely used in clinical practice but the practical
implications remain unclear. For severe RDEB, the gene has been identified as a
possible target for modulation through allogeneic bone marrow transplantation or
induced pluripotent stem cells and a few small clinical trials have shown improvement
(47,48). However, the technology of correcting genetic mutations is still nascent, and
the risk of morbidity and mortality greatly outweigh any potential benefit for patients
with DDEB or EBP. In medical genetics, prenatal diagnosis has been heralded as a
new area of intervention. This endeavor has been attempted for expectant parents with
relatives affected by severe variants of EB such as RDEB and junctional EB and has
been mostly accurate in identifying the mutation using current prenatal sampling and
mutation detection methods (1,49). Yet, the variability of clinical severity in DEB
displayed in our kindred and in others, even within RDEB, (18,25,38) suggest caution
is needed in interpreting the results of mutational analysis.

This case demonstrates the phenotypic complexity and incomplete penetrance of
COL7A1 mutations in an extended kindred with DEB and EBP. The same mutation in
intron 47, c.4668+1 G>A, resulted in a mild EBP in one individual, a severe but timelimited course in another, and no effect in yet another, but caused severe EBP in the
proband that responded to thalidomide treatment after more than ten years of trying
alternative therapies. Additionally, the same mutation caused classic DEB with solely
trauma-induced blistering in another branch of this family. Clinical studies and DNA
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sequencing for five common European variants of filaggrin and an MMP1 promoter
SNP failed to reveal the etiology of the proband’s pruritus. Given that the observed
mutation is predicted to affect splicing, one might speculate that alternative splice
isoforms are expressed in different members of this kindred, though this would not
explain the phenotypic variability seen in the majority of EBP kindreds which carry
missense mutations. We expect that genetic and/or environmental factors are involved
in the initiation and progression of EBP, although the exact mechanisms remain to be
determined. Further elucidation may become permissible with broader availability of
whole genome and transcriptome sequencing and better understanding of common
polymorphisms within the population that may contribute to the pathogenesis of
pruritus and to EBP.
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